Statins reduce spirochetal burden and modulate immune responses in the C3H/HeN mouse model of Lyme disease

详细信息    查看全文

• 作者：Tricia A. Van Laar^a ; ¹ ; Camaron Hole^a ; S.L. Rajasekhar Karna^a ; Christine L. Miller^a ; Robert Reddick^b ; Floyd L. Wormley^a ; J. Seshu^a ; ^{j.seshu@utsa.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Lyme disease ; Borrelia burgdorferi ; Cell wall biogenesis ; Statins
• 刊名：Microbes and Infection
• 出版年：2016
• 出版时间：June 2016
• 年：2016
• 卷：18
• 期：6
• 页码：430-435
• 全文大小：656 K

文摘

Lyme disease (LD) is a systemic disorder caused by Borrelia burgdorferi. Lyme spirochetes encode for a functional 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGR EC 1.1.1.88) serving as a rate limiting enzyme of the mevalonate pathway that contribute to components critical for cell wall biogenesis. Statins have been shown to inhibit B. burgdorferi in vitro. Using a mouse model of Lyme disease, we found that statins contribute to reducing bacterial burden and altering the murine immune response to favor clearance of spirochetes.